Last reviewed · How we verify

Cannabis, Medical

OMNI Medical Services, LLC · Phase 2 active Small molecule

Medical cannabis modulates the endocannabinoid system through cannabinoid receptors (CB1 and CB2) to produce therapeutic effects including pain relief, anti-inflammation, and symptom management.

Medical cannabis modulates the endocannabinoid system through cannabinoid receptors (CB1 and CB2) to produce therapeutic effects including pain relief, anti-inflammation, and symptom management. Used for Chronic pain, Chemotherapy-induced nausea and vomiting, Multiple sclerosis-related spasticity.

At a glance

Generic nameCannabis, Medical
Also known asMarijuana Medical, Marijuana Treatment
SponsorOMNI Medical Services, LLC
Drug classCannabinoid
TargetCB1 receptor, CB2 receptor
ModalitySmall molecule
Therapeutic areaPain Management, Neurology, Oncology, Gastroenterology
PhasePhase 2

Mechanism of action

Cannabis contains multiple cannabinoids, primarily THC and CBD, which bind to CB1 receptors in the central nervous system and CB2 receptors in peripheral tissues and immune cells. These interactions modulate neurotransmitter release, reduce inflammatory signaling, and alter pain perception and nausea pathways. The specific therapeutic effects depend on the cannabinoid profile and route of administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: